BLA 761156 · Novo Nordisk INC
Sogroya
Somapacitan-Beco · Subcutaneous
NovelLast checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Aug 28, 2020
Approved uses
5
Original approval plus efficacy supplements
Registered trials
17
7 Phase 3, 1 recruiting
FAERS reports
181
115 serious, 10 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 25, 2026.
SOGROYA is indicated for the treatment of pediatric patients aged 2.5 years and older with: • Growth failure due to inadequate secretion of endogenous growth hormone (GH). • Short stature born small for gestational age (SGA) and with no catch-up growth by 2 years of age. • Growth failure associated with Noonan syndrome (NS). • Idiopathic Short Stature (ISS). SOGROYA is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD). SOGROYA is a human growth hormone analog indicated for: Pediatric Patients: Treatment of pediatric patients aged 2.5 years and older with: • Growth failure due to inadequate secretion of endogenous growth hormone (GH). ( 1 ) • Short stature born small for gestational age (SGA) and with no catch-up growth by 2 years of age. ( 1 ) • Growth failure associated with Noonan syndrome (NS). ( 1 ) • Idiopathic Short Stature (ISS). ( 1 ) Adults: Replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). ( 1 )
Mechanism: Somapacitan-beco binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor-1 (IGF-1) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 27, 2026 Supplement 15 · Efficacy LetterLabel
- Feb 27, 2026 Supplement 14 · Efficacy LetterLabel
- Feb 27, 2026 Supplement 12 · Efficacy LetterLabel
- Apr 28, 2023 Supplement 5 · Efficacy LetterLabel
- Aug 28, 2020 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
- SOGROYA · SOMAPACITAN-BECO 10MG/1.5ML · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Somapacitan" as an intervention, any sponsor and status, largest first.
- A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to GrowPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05330325 · 412 participants · Start Aug 10, 2022 · Primary completion Aug 5, 2024
Drug: Somapacitan; Norditropin® · For: SGA, Turner Syndrome, Noonan Syndrome, ISS
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 199 sites in all
- Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02229851 · 301 participants · Start Oct 31, 2014 · Primary completion Apr 21, 2017
Drug: somapacitan; somatropin and 1 more · For: Growth Hormone Disorder; Adult Growth Hormone Deficiency
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 117 sites in all
- A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03811535 · 200 participants · Start May 20, 2019 · Primary completion Nov 10, 2021
Drug: Somapacitan; Norditropin® · For: Growth Hormone Deficiency in Children
Sites: Birmingham, Alabama; Los Angeles, California; Madera, California · 139 sites in all
- A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04970654 · 110 participants · Start Jul 22, 2021 · Primary completion Nov 17, 2023
Drug: somapacitan; Norditropin® · For: Growth Hormone Deficiency in Children
Sites: Hefei, China; Beijing, China; Xiamen, China · 32 sites in all
- First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy SubjectsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01514500 · 105 participants · Start Jan 16, 2012 · Primary completion Mar 18, 2013
Drug: somapacitan; placebo (somapacitan) · For: Growth Hormone Disorder; Adult Growth Hormone Deficiency; Growth Hormone Deficiency in Children and 1 more
Sites: Neuss, Germany
- A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone DeficiencyPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02382939 · 92 participants · Start Feb 12, 2015 · Primary completion Jan 4, 2016
Drug: somapacitan; somatropin · For: Adult Growth Hormone Deficiency; Growth Hormone Disorder
Sites: Århus C, Denmark; København Ø, Denmark; Odense, Denmark · 28 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02616562 · 76 participants · Start Mar 31, 2016 · Primary completion Sep 26, 2024
Drug: somapacitan; Norditropin® FlexPro® pen · For: Growth Hormone Disorder; Growth Hormone Deficiency in Children
Sites: Birmingham, Alabama; Los Angeles, California; Madera, California · 89 sites in all
- A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a DayActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03878446 · 62 participants · Start Jul 4, 2019 · Primary completion May 5, 2021
Drug: Somapacitan; Norditropin® · For: Short Stature Children Born Small for Gestational Age (SGA)
Sites: Birmingham, Alabama; Orange, California; Boise, Idaho · 95 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache15
- pyrexia8
- arthralgia7
- fatigue7
- vomiting7
- hospitalisation6
- pain in extremity6
- rash6
- abdominal pain5
- asthenia5
- condition aggravated5
- decreased appetite5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2023 | 8 |
| 2024 | 58 |
| 2025 | 53 |
| 2026 | 60 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sogroya (Somapacitan-Beco)
2024 spending
$1.4M
Beneficiaries
91
455 claims
Per beneficiary
$14,916
$1,316.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $163,197 |
| 2024 | $1,357,313 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.
Miller BS, Blair JC, Rasmussen MH, et al. · J Clin Endocrinol Metab 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
Johannsson G, Gordon MB, Højby Rasmussen M, et al. · J Clin Endocrinol Metab 2020 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis.
de Fries Jensen L, Antavalis V, Odgaard-Jensen J, et al. · Adv Ther 2024 · Comparative Study, Systematic Review
- Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.
Sävendahl L, Battelino T, Højby Rasmussen M, et al. · J Clin Endocrinol Metab 2023 · Clinical Trial, Phase II, Multicenter Study
- Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
Sävendahl L, Battelino T, Brod M, et al. · J Clin Endocrinol Metab 2020 · Clinical Trial, Phase II, Comparative Study
- Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4.
Miller BS, Blair JC, Rasmussen MH, et al. · Eur J Endocrinol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Novo Nordisk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.